NKGen’s Immune Therapy Shows Early Promise in Alzheimer’s Fight

SANTA ANA, CA – March 10, 2026 – In the relentless and often disheartening battle against Alzheimer’s disease, a novel approach using the body's own immune system is showing a glimmer of hope. NKGen Biotech, a clinical-stage company, announced today it will present compelling new analyses from its early-stage trials for an investigational cell therapy, troculeucel, at the prestigious AD/PD™ 2026 conference in Copenhagen later this month.

The presentations will feature an integrated analysis of two completed Phase 1 studies, highlighting a dose-dependent cognitive benefit in patients with moderate Alzheimer's. This data, presented at one of the world's premier neurology conferences, offers a crucial look at a therapy that aims to do what so many others have not: attack the disease on multiple fronts.

A New Immunotherapeutic Approach

Unlike many Alzheimer's drugs that focus on a single target, such as amyloid plaques, troculeucel represents a fundamentally different strategy. It is an autologous natural killer (NK) cell therapy, meaning it harnesses a patient’s own immune cells. These NK cells are extracted, activated, and expanded in a lab, and then re-infused into the patient.

The proposed mechanism is what sets it apart. Research suggests troculeucel works in several ways. First, the therapy appears capable of crossing the heavily fortified blood-brain barrier, allowing the engineered cells to act directly within the central nervous system. Once there, it is designed to reduce neuroinflammation—a key driver of damage in Alzheimer's—by eliminating rogue, over-activated T-cells.

Furthermore, in vitro studies have demonstrated that these enhanced NK cells can actively clear the pathological proteins, including amyloid and alpha-synuclein, that are hallmarks of the disease. By both taming the inflammatory fire and clearing the toxic debris, troculeucel offers a multi-pronged attack on the complex pathology of Alzheimer's.

Decoding the Data: Cognition and Biomarkers

The upcoming oral presentation, titled 'First-in-Class NK Cell Therapy Troculeucel Shows Cognitive Benefit in Moderate Alzheimer’s: Dose Dependent Phase 1 Findings', points to a crucial element for any new drug: a dose-response relationship. This suggests that higher doses of the therapy may be linked to greater cognitive improvements, a strong signal that the drug is having a real biological effect.

Equally significant is the focus of a second poster presentation on plasma Glial Fibrillary Acidic Protein (GFAP). GFAP is a well-established biomarker for brain injury and astrocytic activation—essentially, a biological smoke signal for neuroinflammation and damage. Elevated GFAP levels are strongly correlated with the progression of Alzheimer's and predict faster cognitive decline.

NKGen’s data will explore the link between troculeucel treatment, a reduction in GFAP levels, and cognitive improvement. A therapy that can demonstrably lower GFAP levels would provide objective, biological evidence that it is reducing brain inflammation. According to the company's previous findings, a drop in GFAP appeared to correlate with stabilized or improved cognitive scores, providing a mechanistic link between the therapy's action and its clinical benefit for patients.

High Stakes in a High-Need Field

The potential impact of a successful new Alzheimer's therapy cannot be overstated. With an estimated 55 million people living with dementia worldwide and a new case diagnosed every three seconds, the unmet medical need is staggering. The field is littered with hundreds of failed clinical trials, making any promising signal from a new therapeutic class a significant event.

For NKGen Biotech, the stakes are particularly high. The company faces considerable financial headwinds, having noted in public filings “substantial doubt about the company’s ability to continue as a going concern” and seeing its stock delisted from Nasdaq to the OTC market. This challenging financial backdrop creates a high-pressure environment where positive clinical data is not just beneficial, but essential for survival.

In a sign of internal confidence, the company's CEO, Dr. Paul Song, recently made a significant personal investment to accelerate the ongoing Phase 2 trial. This move underscores the belief within the company that the science is sound, even as it navigates the harsh realities of biotech financing. The data presented at AD/PD™ 2026 could therefore be a pivotal catalyst, potentially attracting the partnerships and investment necessary to carry the therapy forward.

A Glimmer of Hope Tempered with Caution

For patients and their families, any progress offers a much-needed glimmer of hope. Early anecdotes from NKGen's trials have been described by observers as "eye-catching," including one case where a patient reportedly improved from a diagnosis of moderate Alzheimer's to mild cognitive impairment—a remarkable clinical leap.

However, experts urge caution. The data being presented are from small, early-stage Phase 1 trials and represent a new analysis, not new trial results. While promising, these findings are not a substitute for the rigorous, large-scale, placebo-controlled data required for drug approval. The true test for troculeucel will be its performance in the company's ongoing Phase 2 study.

As the scientific community gathers in Copenhagen, the results will be scrutinized for their potential to shift the paradigm of Alzheimer's treatment. While the road ahead is long and uncertain, the innovative approach of harnessing the immune system provides a new and potentially powerful avenue in the enduring quest to conquer this devastating disease.